Primis Financial (NASDAQ:FRST – Get Free Report) is projected to issue its Q3 2025 results after the market closes on Thursday, October 23rd. Analysts expect the company to announce earnings of $0.32 per share and revenue of $27.9610 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, October 24, 2025 at 10:00 AM ET.
Primis Financial (NASDAQ:FRST – Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.13). Primis Financial had a negative net margin of 0.93% and a negative return on equity of 2.02%. The company had revenue of $42.36 million for the quarter, compared to analysts’ expectations of $28.13 million. On average, analysts expect Primis Financial to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Primis Financial Trading Down 1.5%
NASDAQ FRST opened at $10.17 on Thursday. Primis Financial has a 1-year low of $7.59 and a 1-year high of $12.95. The company has a current ratio of 0.98, a quick ratio of 0.95 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $250.59 million, a PE ratio of -113.00 and a beta of 0.81. The firm’s fifty day simple moving average is $10.88 and its 200-day simple moving average is $10.18.
Primis Financial Dividend Announcement
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on FRST. Zacks Research raised Primis Financial from a “strong sell” rating to a “hold” rating in a research note on Monday. Weiss Ratings reiterated a “hold (c)” rating on shares of Primis Financial in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.
Get Our Latest Stock Analysis on FRST
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its position in shares of Primis Financial by 12.6% in the first quarter. Royal Bank of Canada now owns 24,875 shares of the company’s stock valued at $243,000 after purchasing an additional 2,790 shares during the period. AQR Capital Management LLC raised its position in shares of Primis Financial by 25.5% in the first quarter. AQR Capital Management LLC now owns 23,904 shares of the company’s stock valued at $234,000 after purchasing an additional 4,864 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Primis Financial by 11.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,072 shares of the company’s stock valued at $128,000 after purchasing an additional 1,370 shares during the period. Goldman Sachs Group Inc. lifted its position in Primis Financial by 170.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 248,639 shares of the company’s stock worth $2,429,000 after acquiring an additional 156,703 shares during the last quarter. Finally, Empowered Funds LLC lifted its position in Primis Financial by 65.3% during the 1st quarter. Empowered Funds LLC now owns 26,621 shares of the company’s stock worth $260,000 after acquiring an additional 10,515 shares during the last quarter. Institutional investors and hedge funds own 74.96% of the company’s stock.
Primis Financial Company Profile
Primis Financial Corp. operates as the bank holding company for Primis Bank that provides a range of financial services to individuals and small and medium sized businesses in the United States. Its deposit products include checking, NOW, savings, and money market accounts, as well as certificates of deposits.
Read More
- Five stocks we like better than Primis Financial
- How to Calculate Options Profits
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Start Investing in Real Estate
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Conference Calls and Individual Investors
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Primis Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Primis Financial and related companies with MarketBeat.com's FREE daily email newsletter.